Tech Company Financing Transactions
ACELYRIN Funding Round
ACELYRIN secured a $300 million Series C funding round on 9/13/2022. Backers included Access Biotechnology, Cowen Healthcare Investments and Decheng Capital.
Transaction Overview
Company Name
Announced On
9/13/2022
Transaction Type
Venture Equity
Amount
$300,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to continue development of izokibep in hidradenitis suppurativa (HS) and uveitis, explore several potential new indications, and continue to pursue portfolio expansion through high-value business development opportunities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
23371 Mulholland Dr. PMB 417 Woodland Hills
Los Angeles, CA 91364
USA
Los Angeles, CA 91364
USA
Phone
Undisclosed
Website
Email Address
Overview
At ACELYRIN, the patient is at the center of our culture and our business. We are guided by our values of courage, compassion, collaboration, innovation, and a sense of urgency.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shao-Lee Lin
Chief Marketing Officer
Paul Peloso
Chief Operating Officer
Melanie Gloria
President
Robert Carey
Vice President
Terry Bevirt
Vice President
Brian Wiens
VP - Finance
Suzy Buckhalter
VP - Human Resources
Ron Oyston
VP - Manufacturing
Michael Whitmore
VP - Operations
Sarah Honig
VP - Regulatory Affairs
Marc Kubasak
Browse more venture capital transactions:
Prev: 9/13/2022: Opus Security venture capital transaction
Next: 9/13/2022: Andi venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs